Full-Stack Engineering | Rocky Mountain Madman LLC

OpenAI announced on Tuesday, October 20, that it has acquired Orchestra Bio, a four-year-old biotech software startup whose AI agents handle the operational grind of drug development. Terms were not disclosed. Orchestra had reportedly raised around 20 million dollars as of 2025 from backers including Andreessen Horowitz, Atria, and 8VC, according to TechCrunch. Its platform helps biotech companies track the minutiae of getting a drug through development, from finances to resolving scheduling problems with clinical trials.

Read more about OpenAI Buys Orchestra Bio to Put Agents on the Unglamorous Side of Drug Development

OpenAI CEO Sam Altman speaking on stage at TechCrunch Disrupt.

OpenAI is accelerating a fundraising round of about 30 billion dollars that could value the company at more than 1.4 trillion dollars, Reuters reported on Monday, citing people familiar with the matter. The push is deliberately timed ahead of Anthropic's expected stock market debut in mid-November. Existing backers SoftBank Group and Abu Dhabi-based MGX are in talks to join, and OpenAI met with long-only funds and sovereign wealth funds last week, in the same week Anthropic was holding its own investor day. OpenAI and SoftBank declined to comment to Reuters.

Read more about OpenAI Races to Raise 30 Billion Dollars Before Anthropic Sets the Market Price

Anthropic and AI infrastructure provider Nscale are reportedly on the verge of announcing a second compute deal worth 45 billion dollars, according to Bloomberg reporting relayed by TechCrunch on October 19. The talks would come a little over a month after the two companies announced a first 45 billion dollar compute deal. Bloomberg's sources, cited by TechCrunch, cautioned that the talks are still underway and the details could change, and TechCrunch said it had reached out to both companies for comment.

Read more about Another 45 Billion Dollars: Anthropic and Nscale Are Reportedly Talking About Doing It Again